Last reviewed · How we verify
SAR342434
SAR342434 is a monoclonal antibody that targets and inhibits APRIL (A PRoliferation-Inducing Ligand) to reduce B cell activation and autoimmune responses.
SAR342434 is a monoclonal antibody that targets and inhibits APRIL (A PRoliferation-Inducing Ligand) to reduce B cell activation and autoimmune responses. Used for Systemic lupus erythematosus (SLE).
At a glance
| Generic name | SAR342434 |
|---|---|
| Sponsor | Sanofi |
| Drug class | APRIL inhibitor (monoclonal antibody) |
| Target | APRIL (A PRoliferation-Inducing Ligand) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
APRIL is a TNF superfamily member that promotes B cell survival and plasma cell differentiation, contributing to autoimmune disease pathology. By blocking APRIL, SAR342434 reduces pathogenic B cell responses and autoantibody production. This mechanism is particularly relevant in systemic lupus erythematosus and other B cell-driven autoimmune conditions.
Approved indications
- Systemic lupus erythematosus (SLE)
Common side effects
- Infection
- Nasopharyngitis
- Upper respiratory tract infection
Key clinical trials
- A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes (PHASE1)
- Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine (PHASE3)
- Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine (PHASE3)
- Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion (PHASE1)
- A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SAR342434 CI brief — competitive landscape report
- SAR342434 updates RSS · CI watch RSS
- Sanofi portfolio CI